-
Recombinant Human Interferon Alpha 2A (IFN-alpha 2A) is a protein derived from human leukocyte mRNA, expressed in E. coli. It belongs to the Type I leukocyte interferon family. IFN-alpha 2A exhibits antiviral, anti-proliferative, and natural killer cell activities. Clinically, it has applications in treating various oncological and viral diseases.
-
End-to-end process available from transfer, from clone selection to quality control.
-
Recombinant human Interferon alpha 2a (rhIFN alpha 2a) is produced in E. coli using an expression vector driven by the T7 promoter.
Production: 30L fermentation with a yield of around 500 mg/L (unpurified)
Purification: rhIFN alpha 2a will be purified from inclusion bodies by solubilization, refolding and cation exchange chromatography. Final yield of the process is around 35 % (5g of pure protein from the 30L fermentation). The purity of the product is at
least 98% by silver stained SDS-PAGE and HPLC analysis. -
Treatment with interferon supports the functions of the immune system and it is used in the treatment of Chronic Hepatitis, other viral infections and in cancer therapy .
- Patent expired, end-to-end process available for transfer
- Italy
- www.icgeb-bdu.org
- techtransfer@icgeb.org
- ICGEB Trieste, Italy